Nerviano Medical Sciences

The largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.
Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, to be disclosed at the medical oncology meeting AIOM 2014 Nerviano, Italy – October 20, 2014 – Nerviano Medical Sciences announces that results from a single-arm Phase II study of Milciclib in patients with thymic carcinoma and thymoma will be disclosed in a poster discussion session at the XVI Congresso Nazionale AIOM, October 24-26, 2014, Roma. This clinical trial represents collaborative work of Nerviano Medical Sciences with leading cancer... Read more
Novel JAK2 inhibitors discovered by Nerviano Medical Sciences featured on the cover of Bioorganic & Medicinal Chemistry Nerviano - Italy, September 2014- Nerviano Medical Sciences researchers report the discovery, structure guided design, synthesis and biological evaluation of a novel class of JAK2 inhibitors on the journal Bioorganic & Medicinal Chemistry (“Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors”; Read more
Nerviano Medical Sciences' partner Ignyta announces interim data from RXDX-101 phase I clinical trial at 2014 ESMO congress Nerviano, Italy – September 29, 2014 - Nerviano Medical Sciences’ partner Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, presented interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101 in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain. Ignyta reports... Read more


Nerviano Medical SciencesWe fight cancer. Our mission is to identify innovative agents for clinical development in areas of unmet



Nerviano Medical SciencesCLIOSS operates as your partner in the clinical development and life-cycle management



AcceleraAccelera is committed to predicting and managing potential toxic, pharmacokinetic



NerpharmaNerPharMa is a leading player in high-containment contract